Last Updated on September 16, 2023 by The Health Master
This development heralds the advent of abacavir 60 mg, dolutegravir 5 mg, and lamivudine 30 mg tablets for oral suspension, designed to combat HIV-1 infection in pediatric patients.
Revolutionizing Pediatric HIV Treatment
Historical Challenges Addressed
Treating pediatric HIV patients has long been a challenge due to the specialized formulations required for children.
The fixed-dose combination of abacavir 60 mg, dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension comes in a strawberry-flavored solution, making it a palatable option for young patients.
PEPFAR Program Assurance
The USFDA’s tentative approval under the President’s Emergency Plan for AIDS Relief (PEPFAR) program attests to the formulation’s adherence to the highest quality, safety, and efficacy standards.
This milestone assures that the new drug meets all regulatory criteria.
Collaborative Efforts for Global Impact
Partnerships for Progress
Viatris has strategically partnered with key players to ensure the widespread production and distribution of this revolutionary treatment.
Licensing agreements with the Medicines Patent Pool (MPP) and a development pact with ViiV Healthcare (ViiV) and the Clinton Health Access Initiative (CHAI) solidify the commitment to pediatric healthcare.
A Game-Changer for Children Living with HIV
Rakesh Bamzai, President of India, Emerging Asia, and Access Markets at Viatris, expressed enthusiasm about the approval, emphasizing how the single tablet regimen will significantly alleviate the pill burden for children afflicted by HIV.
Sustainable Goals in HIV Care
Empowering Future Generations
This achievement aligns seamlessly with Viatris’ ambitious sustainability goal.
The company aims to provide Antiretroviral (ARV) therapy to a staggering 30 million patients by the end of 2025.
Of this, over two million are children grappling with HIV/AIDS, promising a brighter and healthier future.
Tailored Treatment for Pediatric Patients
The fixed-dose combination of abacavir, dolutegravir/lamivudine is specifically tailored for pediatric patients weighing at least six kg up to <25 kg with HIV-1 infection.
The dosage is determined based on the patient’s weight, ensuring precise and effective treatment.
It’s crucial to note that this treatment is contraindicated in patients with a prior hypersensitivity reaction to abacavir and in HLAB*5701-positive patients.
These considerations are paramount to ensuring patient safety.
Global Reach for Maximum Impact
The tentative USFDA approval paves the way for regulatory authority submissions, large-scale production, and distribution across 123 low- and middle-income countries, in strict accordance with the license agreement.
This global reach promises to transform the landscape of pediatric HIV care on a grand scale.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: